Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baofei + Bufeijianpi + Bufeiyishen granules are a set of three Traditional Chinese Medicine (TCM) herbal formulations developed by Henan University of Traditional Chinese Medicine for the management of chronic obstructive pulmonary disease (COPD). The treatment protocol employs syndrome differentiation, a core principle of TCM, where patients are assigned one of the three formulations based on their specific clinical presentation: Baofei granules for lung qi deficiency, Bufeijianpi granules for pulmonosplenic qi deficiency, and Bufeiyishen granules for lung and kidney qi insufficiency. These herbal extracts are administered as oral granules and have been evaluated in clinical trials to assess their efficacy in reducing the frequency of acute exacerbations and improving lung function and quality of life in patients with mild to moderate COPD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baofei + Bufeijianpi + Bufeiyishen granules.